Hormone replacement therapy (HRT) has become one of the most rapidly evolving areas of women’s health. Yet despite decades of research, many women still believe hormone therapy is unsafe because of information that emerged more than twenty years ago.
Today, physicians recognize that HRT is an umbrella term describing estrogen, progesterone, and, in carefully selected patients, testosterone therapy used to treat symptoms that commonly develop during perimenopause and menopause. Modern treatment is highly individualized and differs substantially from the hormone formulations that generated concern in the early 2000s.
At SoHo Concierge, we believe women deserve an evidence-based discussion about HRT – one that balances the latest scientific evidence with each patient’s individual symptoms, goals, and medical history.
Why the FDA Changed Its Warning on Estrogen Therapy
Much of the concern surrounding hormone therapy began with the landmark Women’s Health Initiative (WHI) study, published in 2002. The study evaluated women with an average age of 63 – many years beyond the onset of menopause – and primarily used oral conjugated equine estrogen combined with a synthetic progestin (medroxyprogesterone acetate). These medications differ significantly from the transdermal estradiol and micronized progesterone commonly prescribed today.
Following publication of the study, the U.S. Food and Drug Administration (FDA) required boxed warnings on estrogen-containing medications in 2003, leading many women and physicians to avoid hormone therapy altogether.
Over the next two decades, however, researchers carefully reanalyzed the WHI data and published numerous additional studies. These demonstrated that healthy women who begin HRT before age 60, or within approximately 10 years of menopause, have a very different risk profile than the older women enrolled in the original trial. Modern transdermal estrogen also bypasses the liver and appears to carry a lower risk of blood clots than oral estrogen.
Recognizing this growing body of evidence, the FDA announced in November 2025 that it would begin removing the broad boxed warnings from menopausal hormone therapy products. In February 2026, the first updated labels were approved, replacing generalized warnings with more individualized, evidence-based prescribing information.
The message is not that hormone therapy is appropriate for every woman – it isn’t. Rather, today’s evidence supports evaluating each woman individually based on her age, symptoms, health history, and personal risk factors.
Understanding Perimenopause and Menopause
Hormonal changes often begin years before menopause itself.
During perimenopause, estrogen and progesterone levels fluctuate unpredictably, producing symptoms long before menstrual periods stop. As women transition into menopause, hormone levels continue to decline.
Common symptoms include:
- Hot flashes and night sweats
- Poor sleep
- Fatigue
- Brain fog
- Mood changes
- Anxiety or irritability
- Reduced libido
- Vaginal dryness
- Pain with intercourse
- Frequent urinary tract infections
- Urinary urgency or frequency
- Joint aches
Many women assume these symptoms are simply part of getting older.
Fortunately, they often are not. Modern hormone therapy can significantly improve quality of life for appropriately selected patients. Studies have demonstrated improvements in vasomotor symptoms, sleep, energy, sexual function, and joint discomfort. Reanalysis of the WHI has also shown no increase in cardiovascular risk among appropriately selected younger women while demonstrating additional benefits such as reduced fracture risk, lower diabetes risk, and decreased overall mortality.
Modern Hormone Therapy: What Treatment Looks Like
Every treatment plan should be individualized. The goal is to prescribe the lowest effective dose while carefully monitoring symptoms and making adjustments over time.
For women experiencing whole-body symptoms such as hot flashes, night sweats, sleep disturbances, or brain fog, transdermal estradiol patches are often the preferred treatment. Because the medication is absorbed through the skin rather than the gastrointestinal tract, it bypasses first-pass liver metabolism and appears to have a lower risk of blood clots than oral estrogen in appropriately selected women.
Women who still have a uterus generally require progesterone in addition to systemic estrogen. Progesterone protects the uterine lining from excessive stimulation by estrogen, reducing the risk of endometrial hyperplasia and cancer. Current evidence suggests that micronized progesterone, which is structurally identical to the progesterone naturally produced by the body, has a more favorable safety profile than many older synthetic progestins and is commonly prescribed as part of modern HRT.
Women whose symptoms are limited primarily to vaginal dryness, painful intercourse, urinary urgency, or recurrent urinary tract infections may not require systemic hormones at all. Instead, low-dose vaginal estrogen can be remarkably effective. Because these preparations act primarily within the vaginal tissues, they have an excellent safety profile for most women and typically begin improving symptoms after several weeks of consistent use.
Regardless of the treatment chosen, close follow-up is essential. Hormone therapy should never be viewed as a one-time prescription but rather as an ongoing partnership between physician and patient, with adjustments made as symptoms and goals evolve.
What About Testosterone?
Although testosterone is often thought of as a male hormone, women naturally produce testosterone throughout their lives.
For carefully selected women – particularly those with hypoactive sexual desire disorder (HSDD) after menopause – low-dose testosterone therapy may improve libido and sexual well-being. Because there are currently no FDA-approved testosterone products specifically for women in the United States, treatment requires careful dosing, physician supervision, and ongoing monitoring to maximize benefits while minimizing potential side effects.
Is HRT Right for Every Woman?
No. Hormone therapy should always begin with a comprehensive medical evaluation.
Women with hormone-sensitive breast cancer, advanced liver disease, or certain other medical conditions may not be candidates for systemic hormone therapy. Women with a history of blood clots also require individualized risk assessment before treatment decisions are made.
Just as importantly, not every woman requires the same type of hormone therapy. Some benefit from systemic estrogen, others need only local vaginal treatment, while many women do well with lifestyle changes alone. The right treatment depends on your symptoms, medical history, and personal goals.
The SoHo Concierge Difference
Hormone therapy is one of the fastest-changing fields in modern medicine. Much of what patients – and even many physicians- learned twenty years ago has been refined by newer research.
At SoHo Concierge, we believe choosing a physician who remains engaged with current medical evidence is just as important as choosing the right treatment itself. Our physicians regularly review emerging research and use evidence-based guidelines to develop personalized treatment plans rather than relying on outdated recommendations or standardized protocols.
As a physician-owned concierge medical practice, we provide extended appointments, direct physician access, same- or next-day visits, and close follow-up after starting therapy. When laboratory monitoring is appropriate, we rely on validated blood testing rather than expensive, non-validated hormone panels to guide treatment.
The Bottom Line
Hormone replacement therapy has undergone a remarkable transformation over the past two decades. For appropriately selected women, modern HRT can safely relieve many of the symptoms associated with perimenopause and menopause while improving overall quality of life.
Because hormone therapy is highly individualized, there is no single regimen that is right for every woman. The best treatment begins with a thoughtful conversation about your symptoms, medical history, and personal goals.
If you’re searching for hormone therapy in Las Vegas, HRT for perimenopause, or menopause treatment from board-certified physicians, the team at SoHo Concierge is committed to providing personalized, evidence-based care to help you feel your best through every stage of hormonal health.
Sources
Abenhaim, H. A., Suissa, S., Azoulay, L., Spence, A. R., Czuzoj-Shulman, N., & Tulandi, T. (2022). Menopausal hormone therapy formulation and breast cancer risk. Obstetrics and Gynecology, 139(6), 1103–1110. https://doi.org/10.1097/AOG.0000000000004723
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. (2013). ACOG Committee Opinion No. 556: Postmenopausal estrogen therapy: Route of administration and risk of venous thromboembolism. Obstetrics and Gynecology, 121(4), 887–890. https://doi.org/10.1097/01.AOG.0000428645.90795.d9
Glynne, S., Simon, J., Branson, A., Payne, S., Newson, L., Manyonda, I., Cleator, S., Douek, M., Usiskin, S., Tobias, J. S., & Vaidya, J. S. (2026). Menopausal hormone therapy for breast cancer patients: What is the current evidence? Menopause, 33(1), 88–117. https://doi.org/10.1097/GME.0000000000002627
Rossouw, J. E., Aragaki, A. K., Manson, J. E., et al. (2025). Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: A secondary analysis of the Women’s Health Initiative randomized clinical trials. JAMA Internal Medicine, 185(11).
The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028